This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643597.
ClinicalTrials.gov Identifier:
NCT02527629
News
Presentation at the 2nd EACTS INNOVATION SUMMIT from 18.-20.04.24 in Paris
Prof. Sarikouch will present current results on decellularized allografts for pulmonary and aortic valve replacement at the upcoming 2nd EACTS INNOVATION SUMMIT, which will be held at Châteauform Les Prés D’Ecoublay. The...
Multi-center study on pediatric aortic valve replacement with decellularized homografts published
Paediatric aortic valve replacement using decellularized allografts: a multicentre update following 143 implantations and five-year mean follow-up. Horke A, Bobylev D, Avsar M, Cvitkovic T, Meyns B, Rega F, Hazekamp M, Cesnjevar...
5-year results from the prospective ARISE trial published in the European Journal of Cardiothoracic Surgery
5-year results from a prospective, single-arm european trial on decellularized allografts for aortic valve replacement-the ARISE study and ARISE registry data. Horke A, Tudorache I, Laufer G, Andreas M, Pomar JL, Pereda D,...
Welcome to ARISE
65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. Current AVR options are, however, limited for young patients - especially female patients - and those unwilling to accept life-long medical anticoagulation with its inherent risks. None of the currently available prostheses for AVR is tailored toward the individual patient or allows for individual regeneration. The ARISE project will bridge this therapeutic gap in a clinical study to determine the feasibility, safety and efficacy of regenerative heart valves for aortic valve replacement.